Determination of a novel steroidal androgen receptor antagonist (Win 49596) in human plasma using solid-phase extraction and high-performance liquid chromatography with ultraviolet detection.
A rapid, sensitive and selective method was developed for the determination of a novel steroidal androgen receptor antagonist (Win 49596, I) in human plasma. The procedure involved extraction from plasma using a solid-phase phenyl support and elution directly onto a reversed-phase C8 column using a mobile phase consisting of 0.2 mol/l sodium acetate buffer at pH 7-acetonitrile (45:55, v/v). Drug was monitored by ultraviolet detection at a wavelength of 238 nm. Linear responses were observed for standards over the range 0.01-5.0 micrograms/ml. The minimum quantifiable level was 0.02 microgram/ml, using a 0.5-ml plasma sample. The precision was 5.5% and the accuracy ranged from -9.4% to 0.23%. The analytical method has been used to quantify I in plasma from dogs and rats and is projected for use with human plasma from clinical trials.
Skee
D M
DM
Department of Drug Metabolism and Pharmacokinetics, Sterling Research Group, Rensselaer, NY 12144.
Cook
J A
JA
Benziger
D P
DP
D000726:Androgen Antagonists / Q000097:blood*; D002851:Chromatography, High Pressure Liquid; D006801:Humans; D011278:Pregnanes / Q000097:blood*; D011720:Pyrazoles / Q000097:blood*; D013056:Spectrophotometry, Ultraviolet
D000726:Androgen Antagonists; D011278:Pregnanes; D011720:Pyrazoles; C060492:zanoterone